About Alzamend Neuro, Inc.


What is Alzheimer's disease?

Alzamend Neuro™ is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer’s. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses


  • The number of Americans projected to be living with Alzheimer’s disease by the year 2050

  • The number of Americans projected currently living with Alzheimer’s disease in 2021

  • The number of Americans that provide unpaid care for people with Alzheimer’s or other Dementias

  • Leading cause of death in the U.S.

  • The estimated number of seniors that will die with Alzheimer’s disease or another dementia

  • Leading cause of death for Americans age 65 and older & Leading cause of disability and poor health for Americans

  • The estimated cost in 2021 of Alzheimer’s disease to the United States.

  • The estimated value of unpaid care to Alzheimer’s patients by their caregivers including family and friends

  • The estimated cost of by 2050 of Alzheimer’s disease to the United States if no treatment or cure is found

  • The estimated number of Americans age 65 and over that are afflicted in 2021 with Alzheimer’s disease